dc.contributor.author | Yildirim, Malik Ejder | |
dc.contributor.author | Karakus, Savas | |
dc.contributor.author | Kurtulgan, Hande Kucuk | |
dc.contributor.author | Kilicgun, Hasan | |
dc.contributor.author | Ersan, Serpil | |
dc.contributor.author | Bakir, Sevtap | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T09:40:45Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T09:40:45Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 0006-2928 | |
dc.identifier.issn | 1573-4927 | |
dc.identifier.uri | https://dx.doi.org/10.1007/s10528-017-9796-7 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/6721 | |
dc.description | WOS: 000405778000004 | en_US |
dc.description | PubMed ID: 28303356 | en_US |
dc.description.abstract | Plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor (Serpine 1), and it inhibits both tissue plasminogen activator and urokinase plasminogen activator which are important in fibrinolysis. We aimed to find whether there is a possible association between PAI-1 level, PAI-1 4G/5G polymorphism, and endometrial cancer. PAI-1 levels in peripheral blood were determined in 82 patients with endometrial carcinoma and 76 female healthy controls using an enzyme-linked immunoassay (ELISA). Then, the genomic DNA was extracted and screened by reverse hybridization procedure (Strip assay) to detect PAI 1 4G/5G polymorphism. The levels of PAI-1 in the patients were higher statistically in comparison to controls (P < 0.001). The distribution of PAI-1 4G/5G polymorphism was quite different between patients and controls (P = 0.008), and 4G allelic frequency was significantly higher in the patients of endometrial cancer than in controls (P = 0.026). We found significant difference between Grade 1 and Grade 2+3 patients in terms of the PAI-1 levels (P = 0.047). There was no association between PAI-1 4G/5G polymorphism and the grades of endometrial cancer (P = 0.993). Our data suggest that the level of PAI-1 and PAI-1 4G/5G gene polymorphism are effective in the formation of endometrial cancer. PAI-1 levels are also associated with the grades of endometrial cancer. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | SPRINGER/PLENUM PUBLISHERS | en_US |
dc.relation.isversionof | 10.1007/s10528-017-9796-7 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | PAI-1 4G/5G polymorphism | en_US |
dc.subject | PAI-1 levels | en_US |
dc.subject | Endometrial cancer | en_US |
dc.subject | Grades | en_US |
dc.title | The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer | en_US |
dc.type | article | en_US |
dc.relation.journal | BIOCHEMICAL GENETICS | en_US |
dc.contributor.department | [Yildirim, Malik Ejder -- Kurtulgan, Hande Kucuk] Cumhuriyet Univ, Dept Med Genet, Fac Med, TR-58140 Sivas, Turkey -- [Karakus, Savas] Cumhuriyet Univ, Dept Obstet & Gynecol, Fac Med, TR-58140 Sivas, Turkey -- [Kilicgun, Hasan] Erzincan Univ, Dept Nutr & Dietet, Fac Hlth Sci, TR-24030 Erzincan, Turkey -- [Ersan, Serpil -- Bakir, Sevtap] Cumhuriyet Univ, Dept Med Biochem, Fac Med, TR-58140 Sivas, Turkey | en_US |
dc.contributor.authorID | Kurtulgan, Hande Kucuk -- 0000-0001-9172-3244; Yildirim, Malik Ejder -- 0000-0003-4386-1583; ERSAN, Serpil -- 0000-0002-8968-4044 | en_US |
dc.identifier.volume | 55 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.endpage | 321 | en_US |
dc.identifier.startpage | 314 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |